• Julien Guihaire, Clark G Owyang, Jai Madhok, Florent Laverdure, Maïra Gaillard, Antoine Girault, Guillaume Lebreton, and Olaf Mercier.
• From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.
• ASAIO J. 2020 Nov 1; 66 (10): 1069-1072.

AbstractExtracorporeal membrane oxygenation (ECMO) is recognized as organ support for potentially reversible acute respiratory distress syndrome (ARDS). However, limited resource during the outbreak and the coagulopathy associated with coronavirus disease 2019 (COVID-19) make the utilization of venovenous (VV) ECMO highly challenging. We herein report specific considerations for cannulation configurations and ECMO management during the pandemic. High blood flow and anticoagulation at higher levels than usual practice for VV ECMO may be required because of thrombotic hematologic profile of COVID-19. Among our first 24 cases (48.8 ± 8.9 years), 17 patients were weaned from ECMO after a mean duration of 19.0 ± 10.1 days and 16 of them have been discharged from ICU.

26 keywords...

hide…